Degang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Degang Li has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Qiuyuan Yao
Colorectal Surgery Division, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
2 shared publications - Sun Yu
Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publications Wenhan Shi
Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publicationsXinmei Lin
Digestive Diseases Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China
2 shared publicationsZitong Zhou
The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, China
2 shared publications- Fan-Biao Kong
Department of Colorectal and Anal Surgery, People’s Hospital of Guangxi Zhuang Autonomous Region & Institute of Minimally Invasive Technology and Applications, Guangxi Academy of Medical Sciences, Nanning, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 14 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis
Early-onset gastric cancer (EOGC), diagnosed before age 50, is characterized by distinct clinicopathological features, though its molecular landscape remai
- 14 January 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessMolecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis
Early-onset gastric cancer (EOGC), diagnosed before age 50, is characterized by distinct clinicopathological features, though its molecular landscape remai
- Open Access
- 16 May 2025
- Published by Springer Nature in Research Square
Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis
Background: Early-onset gastric cancer (EOGC), diagnosed before the age of 50, exhibits distinct clinicopathological and molecular characteristics compared to late-onset gastric cancer (LOGC). However, the molecular landscape of EOGC remains incompletely defined. This study systematically reviews and meta-analyzes the molecular differences between EOGC and LOGC. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science to identify studies comparing the molecular features between EOGC and LOGC. Meta-analyses were performed to assess differences in The Cancer Genome Atlas (TCGA) molecular subtypes, frequently mutated genes, key therapeutic biomarkers, and serum tumor markers. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and heterogeneity was evaluated via the I² statistic. Results: EOGC was associated with a significantly greater prevalence of the genomically stable (GS) subtype (OR = 1.71, 95% CI: 1.37–2.12) and a lower prevalence of the chromosomal instability (CIN) subtype (OR = 0.62, 95% CI: 0.50–0.77). CDH1 mutations were more common in EOGC (OR = 3.56, 95% CI: 2.94–4.31), whereas HER2 expression was significantly lower (OR = 0.55, 95% CI: 0.44–0.68). EOGC patients had a lower prevalence of deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) (OR = 0.25, 95% CI: 0.12–0.53) but higher PD-L1 expression (OR = 2.11, 95% CI: 1.26–3.54). Serum markers such as CEA (OR = 0.43, 95% CI: 0.36–0.51) and CA19-9 (OR = 0.70, 95% CI: 0.58–0.85) were also less frequently elevated in EOGC. Conclusion: EOGC constitutes a biologically distinct subset of gastric cancer, defined by unique genomic, immune, and serological profiles. These differences highlight the need for age-specific diagnostic and therapeutic strategies and emphasize the value of multiomics approaches to further elucidate the molecular basis of early-onset disease.
- 16 May 2025
- Published by Springer Nature in Research Square
Open AccessMolecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis
Background: Early-onset gastric cancer (EOGC), diagnosed before the age of 50, exhibits distinct clinicopathological and molecular characteristics compared to late-onset gastric cancer (LOGC). However, the molecular landscape of EOGC remains incompletely defined. This study systematically reviews and meta-analyzes the molecular differences between EOGC and LOGC. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science to identify studies comparing the molecular features between EOGC and LOGC. Meta-analyses were performed to assess differences in The Cancer Genome Atlas (TCGA) molecular subtypes, frequently mutated genes, key therapeutic biomarkers, and serum tumor markers. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, and heterogeneity was evaluated via the I² statistic. Results: EOGC was associated with a significantly greater prevalence of the genomically stable (GS) subtype (OR = 1.71, 95% CI: 1.37–2.12) and a lower prevalence of the chromosomal instability (CIN) subtype (OR = 0.62, 95% CI: 0.50–0.77). CDH1 mutations were more common in EOGC (OR = 3.56, 95% CI: 2.94–4.31), whereas HER2 expression was significantly lower (OR = 0.55, 95% CI: 0.44–0.68). EOGC patients had a lower prevalence of deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) (OR = 0.25, 95% CI: 0.12–0.53) but higher PD-L1 expression (OR = 2.11, 95% CI: 1.26–3.54). Serum markers such as CEA (OR = 0.43, 95% CI: 0.36–0.51) and CA19-9 (OR = 0.70, 95% CI: 0.58–0.85) were also less frequently elevated in EOGC. Conclusion: EOGC constitutes a biologically distinct subset of gastric cancer, defined by unique genomic, immune, and serological profiles. These differences highlight the need for age-specific diagnostic and therapeutic strategies and emphasize the value of multiomics approaches to further elucidate the molecular basis of early-onset disease.
- Open Access
- 28 November 2014
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (1) , 19-27
Meta-Analysis of Oncological Outcome After Abdominoperineal Resection or Low Anterior Resection for Lower Rectal Cancer
In lower rectal cancer, postoperative outcome is still subject of controversy between the advocates of abdominoperineal resection (APR) and low anterior resection (LAR). Reports suggest that low anterior resection may be oncologically superior to abdominoperineal excision, although no good evidence exists to support this. Publications were identified which assessed the differences comparing 5-year survival, local recurrence, circumferential resection margin rate, complications and so on. A meta-analysis was performed to clarify the safety and feasibility of the two procedures with several types of outcome measures. A total of 13 studies met the inclusion criteria, and comprised 6,850 cases. Analysis of these data showed that LAR group was highly correlated with 5-year survival (pooled OR = 1.73, 95%CI: 1.30–2.29, P = 0.0002 random-effect). And local recurrence rate of APR group was significantly higher than that in LAR group (pooled OR = 0.63, 95%CI: 0.53–0.75, P < 0.00001 fixed-effect). Also, the circumferential resection margin (CRM) were high involved in APR group than in LAR group. (5 trials reported the data, pooled OR = 0.43, 95%CI: 0.36–0.52, P < 0.00001 fixed-effect). Besides, the incidents of overall complications of APR group was higher compared with LAR group (pooled OR = 0.52, 95%CI: 0.29–0.92, P = 0.03 random-effect). Patients treated by APR have a higher rate of CRM involvement, a higher local recurrence, and poorer prognosis than LAR. And there is evidence that in selected low rectal cancer patients, LAR can be used safely with a better oncological outcome than APR. due to the inherent limitations of the present study, for example, the trails available for this systematic review are limited and the finite retrospective data, future prospective randomized controlled trials will be useful to fully investigate these outcome measures and to confirm this conclusion.
- 28 November 2014
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 21 (1) , 19-27
Open AccessMeta-Analysis of Oncological Outcome After Abdominoperineal Resection or Low Anterior Resection for Lower Rectal Cancer
In lower rectal cancer, postoperative outcome is still subject of controversy between the advocates of abdominoperineal resection (APR) and low anterior resection (LAR). Reports suggest that low anterior resection may be oncologically superior to abdominoperineal excision, although no good evidence exists to support this. Publications were identified which assessed the differences comparing 5-year survival, local recurrence, circumferential resection margin rate, complications and so on. A meta-analysis was performed to clarify the safety and feasibility of the two procedures with several types of outcome measures. A total of 13 studies met the inclusion criteria, and comprised 6,850 cases. Analysis of these data showed that LAR group was highly correlated with 5-year survival (pooled OR = 1.73, 95%CI: 1.30–2.29, P = 0.0002 random-effect). And local recurrence rate of APR group was significantly higher than that in LAR group (pooled OR = 0.63, 95%CI: 0.53–0.75, P < 0.00001 fixed-effect). Also, the circumferential resection margin (CRM) were high involved in APR group than in LAR group. (5 trials reported the data, pooled OR = 0.43, 95%CI: 0.36–0.52, P < 0.00001 fixed-effect). Besides, the incidents of overall complications of APR group was higher compared with LAR group (pooled OR = 0.52, 95%CI: 0.29–0.92, P = 0.03 random-effect). Patients treated by APR have a higher rate of CRM involvement, a higher local recurrence, and poorer prognosis than LAR. And there is evidence that in selected low rectal cancer patients, LAR can be used safely with a better oncological outcome than APR. due to the inherent limitations of the present study, for example, the trails available for this systematic review are limited and the finite retrospective data, future prospective randomized controlled trials will be useful to fully investigate these outcome measures and to confirm this conclusion.